Small Interfering RNA (siRNA) Therapeutics Market Key Companies Profile and SWOT Analysis by 2031

MARKET OVERVIEW

Small interfering RNA (siRNA) is a type of genetic medicine, also called silencing RNA, as it can silence any overexpressed genes in diseases. These are most widely used to assess the specific contributions of genes to a variety of cell phenotypes. The siRNAs help recognize novel pathways and validate targets for various life-threatening diseases such as cancer, AIDS, and hepatitis. The cells own enzymes process them to eliminate the mRNA of the target gene to prevent overexpression of the pathogenic gene. They are generally effective than other traditional medicines. The therapy includes liposome-based systemic therapy and nanoparticle-based systemic therapy.

MARKET SCOPE

The "Global Small Interfering RNA (siRNA) Therapeutics Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the small interfering RNA (siRNA) therapeutics market with detailed market segmentation by indication, types, end user, and geography. The report provides key statistics on the market status of the leading small interfering RNA (siRNA) therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

•  Based on indication, the global small interfering RNA (siRNA) therapeutics market is segmented into oncology, cardiovascular diseases, respiratory disorders, neurodegenerative disorders, infectious diseases and other.
  
•  Based on types, the market is segmented into liposome based systemic therapy, nanoparticle based systemic therapy and other.
  
•  On the basis of end-users, the market is bifurcated into diagnostic laboratory, research and academic laboratories.
  

MARKET DYNAMICS

Drivers:

•  High efficiency of the siRNA as compared to previous reverse genetic technologies.
  
•  Rise in the number of clinical trials.
  
•  Rise in the prevalence of cancer.
  
•  The short time of pre-clinical development.
  
•  Increase in the government funding for R&D activities.
  

Restraints:

•  Stringent FDA regulations.
  
•  Changing reimbursement policies.
  

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The small interfering RNA (siRNA) therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the small interfering RNA (siRNA) therapeutics market in these regions.

IMPACT OF COVID-19 ON SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET

COVID-19 initially began in Wuhan (China) in December 2019, and till now, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 pandemic has impacted the worldwide economy at various levels and has become a threat to global health. Due to the shutdown of business units, shortage in the supply of raw materials, and labor, there was a decline in the sales of market players. The shutdown of plants and factories worldwide disturbed the manufacturing, delivery schedules, and product sales. Also, the travel bans imposed by countries affected business collaborations and partnership opportunities. This impacted the small interfering RNA (siRNA) therapeutics market growth. Therefore, the pandemic has significantly affected the market's development and its growth.

MARKET PLAYERS

The report covers key developments in the small interfering RNA (siRNA) therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from small interfering RNA (siRNA) therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for small interfering RNA (siRNA) therapeutics in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the small interfering RNA (siRNA) therapeutics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

•  Horizon Discovery
  
•  GlaxoSmithKline
  
•  Sirna Therapeutics, Inc.
  
•  Alnylam Pharmaceuticals
  
•  Sanofi Genzyme
  
•  Olix Pharmaceuticals
  
•  Silence Therapeutics AG
  
•  Calando Pharmaceuticals
  
•  Arbutus Biopharma Corp
  
•  Sylentis S.A
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Small Interfering RNA (siRNA) Therapeutics Report Scope